EMHA calls for its inclusion in EU neurological health strategy

Three-year data highlights inflammation control in psoriatic arthritis

Rheumatology studies show promising results for Sjogren’s disease

Biotech firm to collaborate with NHS on early detection study

Therapy indicated for children aged 3 to 14 at treatment initiation

New funding supports development of diagnostic platform

Treatment provides option for children with growth failure

Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!

New guidance expands treatment options for eligible patients

Updated guidance from NICE expands eligibility for dapagliflozin us